# Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only

> **NCT00950911** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 35 (actual)

## Conditions studied

- Bone Metastases in Men With Hormone-Refractory Prostate Cancer
- Bone Metastases in Subjects With Advanced Breast Cancer
- Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma

## Interventions

- **DRUG:** amg 162

## Key facts

- **NCT ID:** NCT00950911
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2012-02
- **Final completion:** 2012-04
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2014-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00950911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00950911, "Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00950911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*